Executive Summary
•Euroz Hartleys is undergoing a fundamental strategic transformation following the sale of its Capital Markets business to BMO Financial Group, transitioning toward a pure Private Wealth and asset management model with a materially smaller revenue base but higher quality recurring earnings.
•Reported FY2026 EPS of 10.74 cents is heavily inflated by one-time gains from the Capital Markets divestment, while underlying H2 net income ex-items declined to $2.8m from $4.0m YoY, signalling earnings pressure in the core wealth franchise during the transition period.
•Trading at ~12.6x reported FY2026 P/E but closer to 18-20x on underlying earnings ex-divestment gains, the stock is priced for a successful wealth management transition that has yet to be fully demonstrated in recurring revenue growth.
•Strong balance sheet with $23.1m returned via capital reduction and net assets of ~$96m provides downside support, but the small-cap profile ($126m market cap) and reduced earnings visibility post-divestment create elevated risk for institutional investors.
Financial Snapshot
•Revenue (TTM): $140.9m
•Gross Margin: 93.9%
•Operating Margin: 12.2%
•Net Margin: 11.8%
•ROE: 15.9%
•Debt/Equity: 12.6%
•Market Cap: $125.8m
•Total Assets: $201.6m (as at 30 June 2026)
•Total Liabilities: $105.5m
•Capital returned to shareholders: $23.1m
•Reported FY2026 EPS: 10.74 cents (vs 6.54 cents prior year)
•Underlying H2 FY2026 net income ex-items: $2.8m (vs $4.0m YoY)
•Underlying H2 FY2026 basic EPS: 1.83 cents (vs 2.56 cents YoY)
Forward Outlook
•Revenue trajectory: Post-divestment of Capital Markets, forward revenue will be materially lower as the broking and corporate advisory stream is removed, with the Private Wealth segment expected to generate the majority of recurring income.
•EPS estimates: Underlying EPS likely normalises to approximately 5-7 cents per share on an annualised basis post-transition, implying the 10.74 cents reported figure is heavily distorted by one-time divestment gains.
•Margin trajectory: Gross margin should remain elevated (~90%+) given the asset-light wealth management model, but operating margins may compress in the near term as fixed costs absorb a smaller revenue base before operating leverage kicks in.
•Capital returns: The $23.1m capital reduction signals management's willingness to return excess capital, though future distributions will depend on the earnings power of the streamlined business.
Valuation Analysis
Trailing Multiples
•TTM P/E: ~12.6x (on reported FY2026 EPS of 10.74 cents, distorted by divestment gains)
•TTM P/S: 0.89x
•Underlying P/E (ex-divestment gains): ~18-22x on estimated normalised EPS of 6-7 cents
Forward Multiples
•NTM P/E: ~18-22x (estimated, pending full Private Wealth standalone financials)
•NTM P/S: ~1.2-1.5x (estimated, on reduced revenue base post-Capital Markets exit)
•NTM EV/EBIT: Not disclosed (insufficient forward EBIT guidance)
Peer Comparisons
•SHL.AX: ~15.9x TTM P/E, large-cap healthcare diagnostics, not directly comparable
•VSL.AX: ~46.9x TTM P/E, growth-oriented lithium play, not directly comparable
•Comparable financial services peers (Australian wealth managers/brokers) typically trade at 8-15x earnings depending on recurring revenue mix and AUM growth
Valuation Framework
•DCF: With WACC of 9.5% and terminal growth of 2.5%, a fair value range of $1.20-$1.40 is supported assuming normalised EPS of 6-7 cents and modest mid-cycle growth in funds under advice.
•Price target: $1.30-$1.45 range, reflecting the transition risk offset by balance sheet strength.
Key Risks & Catalysts
Risks
•Earnings durability: Underlying H2 FY2026 net income ex-items declined 30% YoY ($2.8m vs $4.0m), raising questions about the sustainability of the Private Wealth franchise as a standalone entity.
•Revenue concentration: Post-divestment, the company is heavily reliant on Private Wealth fees and advisory commissions, creating revenue concentration risk in a narrower business mix.
•Market dependency: Wealth management revenue is highly correlated to equity market performance and client trading activity, creating cyclical earnings volatility.
•Small-cap liquidity: $126m market cap limits institutional interest and creates liquidity constraints, potentially leading to persistent trading discounts to fundamental value.
•Transition execution risk: Integration and restructuring costs associated with the Capital Markets divestment may pressure near-term margins and distract management from client growth initiatives.
•Key personnel retention: The Capital Markets sale may trigger departures of revenue-generating advisers, potentially eroding the client base and AUM.
Catalysts
•Successful redeployment of divestment proceeds into accretive acquisitions or share buybacks at current depressed multiples.
•Growth in funds under advice driven by the transition to recurring fee-based wealth management revenue, improving earnings quality and predictability.
•Material capital return or special dividend following the completion of the BMO transaction, unlocking value for shareholders.
•Re-rating upon demonstrated stability of the standalone Private Wealth P&L, particularly if underlying margins expand beyond 15% through operating leverage.
Investment Thesis
Euroz Hartleys presents a classic small-cap special situation: a company in transition with a strong balance sheet but uncertain forward earnings power. The sale of the Capital Markets business to BMO simplifies the narrative but removes a material revenue stream, and the H2 FY2026 underlying earnings decline of 30% YoY is a red flag that the market is correctly pricing with scepticism. At $1.35, the stock trades near the midpoint of its 52-week range and at a premium to underlying earnings once divestment gains are stripped out.
The bull case rests on the Private Wealth franchise scaling into a higher-margin, recurring-revenue model with capital returned to shareholders. The $23.1m capital reduction demonstrates management's shareholder-friendly approach, and the net asset backing of ~$96m provides a tangible floor. However, until the company demonstrates stabilised post-transition earnings with a clear path to growth in funds under advice, the stock is likely to remain range-bound. I would recommend a HOLD/ACCUMULATE on weakness below $1.25, targeting $1.40-$1.45 on evidence of earnings stabilisation and margin recovery in the standalone business. The asymmetric risk-reward improves significantly at lower entry points where the balance sheet provides greater downside protection.
